Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)

• المؤلفون الرئيسيون: Eréndira Mejía-Aranguré (مؤلف), Alfonso Reyes-López (مؤلف), Luis Enrique Juárez-Villegas (مؤلف), Yosef Olaf Hernández-Olivares (مؤلف), Alberto Daniel Saucedo-Campos (مؤلف), Gabriela Hernández-Pliego (مؤلف), Silvia Martínez-Valverde (مؤلف), Leticia A. Barajas-Nava (مؤلف), Juan Garduño-Espinosa (مؤلف)
• التنسيق: كتاب
• منشور في: BMC, 2022-12-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Background ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount f...